A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours

← catalyst calendar

NCT07441707 · readout in 1,442 d

Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

6estimated

Sites

Country

Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-03

actual

When the study began enrolling

Primary completion

2030-07-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-07-31

estimated

The whole study's end, after follow-up

First posted

2026-03-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-30

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Low-grade Glioma

Intervention

Drug: Tovorafenib — also filed as Ojemda®

Primary outcomes

what the primary-completion date above is the date OF

Percentage of participants experiencing Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

measured From first dose until 30 days post-treatment

Percentage of participants experiencing Serious Adverse Events (SAEs) and AESIs

measured Up to 4 years from first dose, including post-treatment monitoring

Area under the plasma concentration-time curve from time zero to last measurable concentration (AUC₀-t) of tovorafenib following a single dose